ProShares UltraShort Nasdaq Biotechnology ETF (BIS) - NASDAQ
  • Wed, Jan. 27, 3:30 PM
    • As if biotech investors need reminding, biotechs (and healthcare stocks) are getting some rude treatment today, the market's foul mood notwithstanding. The Nasdaq Composite Index is down 2.5%,but the SPDR S&P Biotech ETF (XBI -4.7%) almost twice as much. The iShares Nasdaq Biotechnology ETF (IBB -3.5%) is faring a bit better, but still down more than the broad market.
    • Only Biogen and Abbott have bucked the trend.
    • Sample of tickers: (AMGN -2.5%)(BIIB +5.7%)(CELG -3.9%)(GILD -3.3%)(ALXN -1.2%)(ABT +0.3%)(BMY -1.8%)(MRK -3%)(VRX -4%)(PFE -0.9%)
    • ETFs: BIB, BIS, CNCR
    | Wed, Jan. 27, 3:30 PM | 63 Comments
  • Thu, Jan. 14, 10:57 AM
    • Biotechs are moving in sync with the market today. The iShares Nasdaq Biotech Index Fund (IBB +1.8%) is up ~4% from its low of 273.47, outpacing the Nasdaq Composite's 2.6% jump from its intraday low of 4,470.59. The IBB had lost over 20% of its value since late December.
    • ETFs: BIB, GRX, IRY, BIS, IXJ, BME, CNCR, THW
    | Thu, Jan. 14, 10:57 AM | 2 Comments
  • Oct. 21, 2015, 1:22 PM
    • As if anyone following biotechs needs reminding, sellers are overwhelming the space. The iShares Nasdaq Biotechnology ETF (IBB -2.8%) is down 6% since Monday.
    • Key tickers: (BIB -6.5%)(BIS +6.3%)(VRX -38.5%)(AGN -5.9%)(BIIB -0.1%)(AMGN -1.7%)(GILD -1%)(CELG -2%)
    | Oct. 21, 2015, 1:22 PM | 66 Comments
  • Oct. 5, 2015, 5:41 PM
    • Top gainers, as of 5.25 p.m.: ARNA +6.1%. DD +5.3%. RKUS +4.0%. BIS +3.5%. JCP +1.4%.
    • Top losers, as of 5.25p.m.: ILMN -14.0%. HAE -12.1%. TCS -10.0%. ABY -5.3%. RIG -4.1%.
    | Oct. 5, 2015, 5:41 PM | 10 Comments
  • Jul. 31, 2015, 7:52 AM
    • According to Reuters, the value of merger and acquisition deals through July 30 was $436.4B, including 14 deals worth over $5B apiece. Although down from June's torrid pace of $546.8B, it still ranks as the seventh busiest month on record. Leading the pack was Teva's $40.5B purchase of Allergan's generic drugs business.
    • The top investment bank in terms of the total value of transactions was Goldman Sachs (NYSE:GS), involved in 35 deals worth $148.8B, including half of the top ten. JP Morgan (NYSE:JPM) was second with 30 deals worth $116.1B while Morgan Stanley (NYSE:MS) was third with 33 deals valued at $95.9B.
    • Global M&A so far this year is $2.64T, up 41% from last year. The action in the U.S. is up 66%.
    • Energy and healthcare are the leading sectors. There have been 1,557 deals in energy worth $407B. Healthcare is close behind with 1,577 deals worth $395B.
    • ETFs: UNG, USO, OIL, UGAZ, UCO, DGAZ, UWTI, BIB, SCO, BNO, BOIL, GAZ, DBO, DWTI, DTO, UGA, KOLD, USL, GRX, UNL, IRY, BIS, IXJ, DNO, BME, UHN, DBE, OLO, SZO, DCNG, GRN, RJN, FUE, OLEM, JJE, ONG, UBN
    | Jul. 31, 2015, 7:52 AM | 1 Comment
  • Apr. 29, 2015, 12:42 PM
    • The biotech sector heads south again today, continuing the move that began in earnest on Monday. The iShares Biotechnology ETF, for example, is down over 8% from the March 29 high of 374.97 and down almost 7% from the intermediate high of 368.25 on April 23. This phase of the down move is particularly bearish considering the high volume driving the drops on Monday and Tuesday (2.3x normal volume both days).
    • A correction is not that surprising in light of the uninterrupted one-year uptrend. On a technical basis, IBB longs should look for support at 320.
    • ETFs: IBB, BIB, BIS
    | Apr. 29, 2015, 12:42 PM | 5 Comments
  • Mar. 25, 2015, 12:13 PM
    • The Nasdaq's down move notwithstanding, the biotech sector is selling off on higher-than-normal volume today. On a technical basis, a correction (or at least a pause) is due. Prices pierced their upper price channel last week on robust volume. This is classic pre-correction behavior at the end of a long uninterrupted bull run, which began for biotechs almost a year ago. Look for more near-term weakness before prices consolidate.
    • ETFs: IBB, BIB, BIS
    | Mar. 25, 2015, 12:13 PM | 23 Comments
  • Dec. 23, 2014, 10:40 AM
    | Dec. 23, 2014, 10:40 AM | 28 Comments
  • Oct. 2, 2014, 4:50 PM
    • Regardless of the Mr. Market's mood, there is always some action in the biotech arena. Today, recent-IPO Kite Pharma (KITE +22.5%) jumped to an all-time high of $35.39 on a 6x surge in volume as CNBC was highlighting a bullish opinion on the stock by Oppenheimer with a $73 PT despite the company being years away from generating any product revenue. Kite now sports a market cap of $1.3B.
    • The clinical-stage biopharmaceutical firm develops cancer immunotherapeutics based on its engineered autologous cell therapy (eACT) platform which involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). The modified T cells recognize and destroy cancer cells.
    • Kite's lead product is the CAR-based therapy, KTE-C19, for the treatment of patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). It plans to conduct a Phase 1/2 clinical trial in 2015 and, if the data are compelling, file a BLA with the FDA for accelerated approval. Regulatory clearance probably will not occur before mid-to-late 2016, however.
    • There is reason for optimism. On August 25, the company announced interim results from an ongoing 13-patient Phase 1/2 study of KTE-C19 in DLBCL funded by Kite and conducted at the National Cancer Institute. Patients treated with KTE-C19 demonstrated a 92% response rate (12/13). Eight patients had complete remissions.
    • ETFs: IBB, BIB, BIS
    | Oct. 2, 2014, 4:50 PM
  • Apr. 25, 2014, 1:31 PM
    • Today's selloff is following the pattern of most in the past few weeks, with the small caps (IWM -1.9%) and tech (QQQ -1.5%) leading the way. Pacing declines in the Nasdaq are a 8.8% dive in Amazon post-earnings and a 4.6% fall in Facebook. Setting tongues wagging in FB - but hardly a huge deal - is the sale of another 283K shares by Sheryl Sandberg, bringing her holdings down to 8.7M shares.
    • The liquidation in biotech has previously been a convenient excuse for small cap selloffs, but the IBB is off just 1.4% today, outperforming the Russell 2000.
    • What's working? Utilities again. The XLU +0.8% today and +13% this year, outperforming the Russell 2000 by about 1.6K basis points.
    • Small cap ETFs: IWM, TZA, TNA, UWM, VB, IJR, SLY, RWJ, URTY, SCHA, TWM, RWM, SRTY, SAA, DWAS, VTWO, SDD, VIOO, JKJ, RSCO, SBB, FYX, XSLV, EWRS, TWOK, SMLV, PXSC
    • Utility ETFs: XLU, IDU, VPU, NLR, GRID, JXI, NUCL, DBU, IPU, UPW, RYU, PUI, FUTY, FXU, SDP, PSCU, UTLT
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Apr. 25, 2014, 1:31 PM | 7 Comments
  • Apr. 10, 2014, 11:09 AM
    | Apr. 10, 2014, 11:09 AM | 6 Comments
  • Jan. 28, 2014, 9:12 AM
    • Deutsche's Robyn Karnauskas makes a big call on big-cap biotechs, boosting price targets for Biogen (BIIB) to $415 from $340, Celgene (CELG) to $190 from $170, and Gilead (GILD) to $132 from $95. The $132 PT for Gilead is a new Street high "by a nautical mile," says Notable Calls, and Karnauskas sees upside all the way to $165.
    • "We view large-cap biotech as fundamentally stable yet providing attractive growth," she writes, citing more diversified businesses, pipelines, new product launches, strong balance sheets, and strong free cash flow. "Therefore, we are changing our valuation methodology to 2015 PE multiples from DCF for Gilead, Celgene, and Biogen. Our '15 EPS estimates are higher than consensus and we think near-term franchise success could drive re-rating."
    • GILD +2.7%, CELG +1.3% premarket
    • Related ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Jan. 28, 2014, 9:12 AM | 1 Comment
  • Jan. 27, 2014, 10:52 AM
    • A little bit more air comes out of the previously scorching small-cap biotech names today. Among them: CytRx (CYTR -4.8%), Dyax (DYAX -5.2%), Galena (GALE -9.6%), Novavax (NVAX -9%), Arena (ARNA -6.3%), Synta (SNTA -10.8%), Zogenix (ZGNX -3.5%), Tonix (TNXP -8.4%).
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Jan. 27, 2014, 10:52 AM | 23 Comments
  • Oct. 10, 2013, 11:57 AM
    • Biotechs took a beating in the first three days of this week but they're rallying today, so investors need to decide whether they should be using the dip to buy or the bounce to sell.
    • Citi sees a mixed view for the sector: Given the scarcity of growth stocks in the overall market, the firm expects large-cap biotechs to bounce back but is far less sanguine about small- and mid-caps where valuations are broadly stretched and the Street is overly optimistic of the chances for pipeline success.
    • The firm's favorites include Gilead (GILD +4.7%) and Celgene (CELG +3.5%), and sees compelling risk/reward in Medivation (MDVN +3.9%) and Tesaro (TSRO +5.7%).
    • ETFs: IBB, XBI, FBT, PBE, BBH, BIB, BIS.
    | Oct. 10, 2013, 11:57 AM
  • Sep. 26, 2013, 10:43 AM
    • Cramer says biotech is a safe haven amid the uncertainty emanating from Washington, as pipelines are strong and the sector is not sensitive to the trajectory of the overall economy — this is a "double advantage", he says.
    • Celldex (CLDX +5.3%) — which is part of this week's billion dollar biotech price target bump club courtesy of Leerink and Cantor  — gets a glowing recommendation as Cramer calls the company "just incredible."
    • Other companies getting a name drop: Celgene (CELG +2.4%), Immunogen (IMGN +2%), and Onyx (ONXX).
    • ETFs - IBB, XBI, FBT, PBE, BBH, BIB, BIS
    | Sep. 26, 2013, 10:43 AM
  • Mar. 12, 2012, 12:07 PM
    Shares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector.
    | Mar. 12, 2012, 12:07 PM
BIS Description
ProShares UltraShort Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the inverse (opposite) of the daily performance of the NASDAQ Biotechnology® Index.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub